Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
SSY Group ( (HK:2005) ) has issued an announcement.
SSY Group Limited has announced that its drug Riluzole has received approval from the National Medical Products Administration of China for market use as a bulk drug. This development is significant as Riluzole is used to extend the life of patients with amyotrophic lateral sclerosis (ALS) or delay the need for mechanical ventilation. The approval marks a crucial step in SSY Group’s product development, potentially enhancing its market position and offering new treatment options for ALS patients.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$5.20 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of medical products. The company is engaged in creating drugs that cater to various health conditions, with a particular emphasis on innovative solutions for critical illnesses.
Average Trading Volume: 6,910,561
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.56B
For a thorough assessment of 2005 stock, go to TipRanks’ Stock Analysis page.